Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6–7 Months of age: A Phase 1/2 Randomized TrialXavier Sáez‐Llorens, Nicolas Vanhoutte, Marisa Márcia Mussi‐Pinhata et al.|The Journal of Infectious Diseases|2023Cited by 13